ANN ARBOR, Mich., April 26, 2012 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic
DNA-based therapeutics and innovative disease-modifying medicines
for serious illnesses, announced today the release of its investor
relations mobile iPhone App, called the "SYN IR" App, now available
for free at the Apple App Store on the iPhone or iPad or at
http://bit.ly/I9xDpW.
The Synthetic Biologics' investor relations mobile iPhone App
allows users to navigate the Company's investor relations materials
as well as receive a stock quote and other important stock
information. Features in the "SYN IR" App include the latest press
releases and SEC filings as well as a corporate fact sheet and
listing of events.
"The launch of our investor relations iPhone App provides our
current and potential shareholders with immediate access to
financial and corporate information regarding the Company," stated
C. Evan Ballantyne, Chief Financial
Officer at Synthetic Biologics. "With investors always on the move
and spanning the globe, we recognize the growing importance of
mobile technology. This new application allows our shareholders to
have instant access to our corporate and stock information. We are
excited to be one of the early adopters of mobile technology that
is intended to help drive shareholder value and create broader
awareness throughout the investment community."
About Synthetic Biologics, Inc.
Synthetic Biologics is a biotechnology company focused on the
development of synthetic DNA-based therapeutics and innovative
disease-modifying medicines for serious illnesses. Synthetic
Biologics is developing, or has partnered the development of,
product candidates for the treatment of pulmonary arterial
hypertension (PAH), relapsing-remitting multiple sclerosis (MS),
cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral
sclerosis (ALS). For more information, please visit Synthetic
Biologics' website at www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic
Biologics' current expectations and projections about future
events. In some cases forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are difficult
to predict and include statements regarding driving shareholder
value. The forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from those set forth or implied by any forward-looking statements.
Important factors that could cause actual results to differ
materially from those reflected in Synthetic Biologics'
forward-looking statements include, among others, a failure of the
"SYN IR" App to provide its anticipated benefits and other factors
described in Synthetic Biologics' report on Form 10-K for the year
ended December 31, 2011 and any other
filings with the SEC. The information in this release is provided
only as of the date of this release, and Synthetic Biologics
undertakes no obligation to update any forward-looking statements
contained in this release on account of new information, future
events, or otherwise, except as required by law.
SOURCE Synthetic Biologics, Inc.